Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2003
10/15/2003EP1351972A1 Lipids comprising an aminoxy group
10/15/2003EP1351966A1 Improved specificity in treatment of diseases
10/15/2003EP1351720A1 Hydrocolloid compositions
10/15/2003EP1351712A2 Targeted combination immunotherapy of cancer and infectious diseases
10/15/2003EP1351710A2 Compositions containing inclusion complexes
10/15/2003EP1351709A2 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
10/15/2003EP1351708A1 Therapeutic agent comprising a b-subunit of a protein toxin
10/15/2003EP1351704A2 Storage stable powder compositions of interleukin-4 receptor
10/15/2003EP1351700A2 Conjugates of nucleosides with lactosaminated human albumine
10/15/2003EP1351696A2 Composition for delivery of hematopoietic growth factor
10/15/2003EP1351695A1 Camptothecin compounds with a sulfhydryl group
10/15/2003EP1351693A1 Novel method and compositions for local treatment of meniere's disease, tinnitus and/or hearing loss
10/15/2003EP1351692A1 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
10/15/2003EP1351690A2 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
10/15/2003EP1351685A2 Stabilized formulation of selective ligands of retinoic acid gamma-receptors
10/15/2003EP1351679A2 Method and composition for the treatment of diabetic neuropathy
10/15/2003EP1351673A1 Compositions of stable t 3? and methods of use thereof
10/15/2003EP1351669A1 Clear propofol compositions
10/15/2003EP1351668A1 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
10/15/2003EP1351648A2 Carrier vectors through an epithelium with tight junctions
10/15/2003EP1351585A1 Ingestible compositions containing an odoriferous oil
10/15/2003EP1244427B1 Pharmaceutical compositions for oral administration
10/15/2003EP1231909B1 Use of ubiquinone q10 for the local treatment and prevention of post-surgical ophthalmologic pathologies
10/15/2003EP1100459B1 Foaming oil preparation and its use
10/15/2003EP1094796B1 Topical plaster with non-steroidal antirheumatic agents with an acid group
10/15/2003EP1062259B1 Biodegradable polymers based on natural and renewable raw materials, especially isosorbite
10/15/2003EP1007096B1 Arginine silicate inositol complex and use thereof
10/15/2003EP0975370B1 Composition and method for enhancing transport across biological membranes
10/15/2003EP0876140B1 Improved kontrast agent solutions for intravenous administration
10/15/2003EP0874558B1 Liquid oral compositions comprising a calcium compound and an acidulant
10/15/2003EP0827398B1 Pharmaceutical dosage form for colonic delivery
10/15/2003EP0771339B1 Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
10/15/2003EP0750494B1 Hydrophobic drug delivery systems
10/15/2003CN1449412A DDS compound and process for the preparation thereof
10/15/2003CN1449292A Solution preparations stabilized over long time
10/15/2003CN1449289A Oct制剂 Oct preparations
10/15/2003CN1449280A Rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities
10/15/2003CN1449279A Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
10/15/2003CN1449278A Lung surfactant compositions with dynamic swelling behaviour
10/15/2003CN1449273A Antimicotic nail varnish composition
10/15/2003CN1449272A 硬胶囊 Hard Capsules
10/15/2003CN1449270A Topical compositions containing prostaglandin e1
10/15/2003CN1448184A Injectable pharmaceutical composition containing non-steroid antiphlogistic medicament and method for making same
10/15/2003CN1448132A Modified antineoplastic preparation based on Paclitaxel
10/15/2003CN1448129A Garlicin and garlic oil cyclodextrin derivatives inclusion compound and method for making same
10/15/2003CN1448128A Process for producing nanoparticles of paclitaxel and albumin
10/15/2003CN1448121A O/W/O type polyphase emulsion
10/15/2003CN1124352C Oligosaccharide-supplying compositions
10/15/2003CN1124157C Pharmaceutical compositions
10/15/2003CN1124134C Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, ihibitor of macrophage-lipid complex accumulation on the arterial wall and preven
10/15/2003CN1124130C Pharmaceutical preparation comprising colodronate as active ingredient and silicified microcrystalline cellulose as excipient
10/15/2003CN1124126C Refreshing compositions
10/14/2003US6632980 Chromosomally-integrated inactive replicon derived from geminiviruses and single-stranded RNA viruses; cis-acting viral elements for replication; target gene with regulatory sequence
10/14/2003US6632928 Immunotoxins and methods of inducing immune tolerance
10/14/2003US6632845 Method for improving muscle control and muscle tone and improving sensory integration
10/14/2003US6632842 Reducing medication error and enhancing therapeutic compliance of an individual suffering from COPD by providing a single use inhaler
10/14/2003US6632841 Not in the form of cyclodextrin inclusion complex; in solution with lactic acid as solubilizer
10/14/2003US6632804 Therapeutically effective amount of ferrous ion and a therapeutically effective amount of an ascorbate
10/14/2003US6632803 Pharmaceutical formulations containing voriconazole
10/14/2003US6632799 Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
10/14/2003US6632789 Contacting with inhibitor or activator of phosphatidylinositol 3-kinase
10/14/2003US6632671 Nanoparticle encapsulation system and method
10/14/2003US6632648 Methods of terminal sterilization of fibrinogen
10/14/2003US6632458 Food using γ-aminobutyric acid-enriched cruciferous plant
10/14/2003US6632454 Multilayer pharmaceutical product for release in the colon
10/14/2003US6632452 Medicinal compositions retarded in the discoloration of phenolic hydroxyl compounds
10/14/2003US6632443 Water-soluble compositions of bioactive lipophilic compounds
10/14/2003US6632440 Chronic obstructive pulmonary disease (COPD), asthma; Aerosol administration a compound that inhibits exocytosis in mucus secreting cells produced by modifying a clostridial neurotoxin
10/14/2003US6632437 Immunogenic polysaccharide-protein conjugates containing poly α(2→8), α(2→9) NeuNAc capsular polysaccharides
10/14/2003US6632423 To prevent or reduce fibrosis and/or adhesion in traumatized tissues, comprising the administration of a stabilizing effective amount of the agent to the traumatized tissue
10/14/2003US6632389 Underwater or under-hydrocarbon pelletizing of biologically-active-compound-containing melts
10/14/2003US6632176 Products and methods for brachytherapy
10/14/2003CA2340221C Injectable formulations of nanoparticulate naproxen
10/14/2003CA2271865C Tablet composition
10/14/2003CA2225601C New stable pharmaceutical preparation for producing propellant-free aerosols
10/14/2003CA2118517C Surface modified nsaid nanoparticles
10/14/2003CA2098242C Surface modified anticancer nanoparticles
10/14/2003CA2085827C Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
10/14/2003CA2082740C Controlled release device
10/14/2003CA2074820C Improved cyclodextrin based erythropoietin formulation
10/09/2003WO2003082926A2 Antimicrobial polymer conjugates
10/09/2003WO2003082845A1 Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same
10/09/2003WO2003082360A1 Drug delivery particle
10/09/2003WO2003082359A1 Tissue treatment
10/09/2003WO2003082349A1 Treatment methods for eotaxin mediated inflammatory conditions
10/09/2003WO2003082348A1 Nanogel networks including polyion polymer fragments and biological agent compositions thereof
10/09/2003WO2003082344A1 Remedies with the use of hollow protein nanoparticles presenting growth factor or the like
10/09/2003WO2003082343A1 Drugs for treating liver diseases with the use of hollow protein nanoparticles
10/09/2003WO2003082341A1 AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO[3,4-d] PYRIMIDINES AS KINASE MODULATORS
10/09/2003WO2003082340A1 Injectable veterinary composition for small animals
10/09/2003WO2003082330A1 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
10/09/2003WO2003082329A2 Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
10/09/2003WO2003082323A1 A composition and method for killing of tumours
10/09/2003WO2003082321A1 Dental viscous pharmaceutical containing basic fibroblast growth factor
10/09/2003WO2003082313A1 Co-beadlet of dha and rosemary and methods of use
10/09/2003WO2003082297A1 Meloxicam suppositories containing e.g. polyethylenglycol
10/09/2003WO2003082285A1 Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
10/09/2003WO2003082279A1 Solid preparation containing single crystal form
10/09/2003WO2003082273A1 Solubilization of weak bases
10/09/2003WO2003082253A1 A method for treating carrier particles and its use
1 ... 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 ... 1712